SEAAIS 2019: 74th Annual Meeting

Amelia Island, FL US
September 19, 2019 to September 22, 2019

The purpose of this meeting is to engage the participants through oral didactic presentations followed by group discussions.  Each presentation is reflective of a need or interest of in-depth conversation or study requested by the membership and/or board.  Case presentations are often utilized to solidify the objectives covered in each presentation.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Southeastern Allergy, Asthma and Immunology (SEAAIS).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of  12.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by independent educational grants from CSL Behring, Kaleo, Pharming and Stallergenes Greer.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity, participants should be able to:

1.  Report the efficacy and safety data on approved monoclonals for asthma.
2.  Examine Peanut OIT emerging therapy and treatment options for peanut allergy patients.
3.  Analyze the correlation of some infectious diseases with allergy/immunology.
4.  Differentiate causes of chronic cough and compare new thoughts on treatment.
5.   Review common dermatologic conditions treated by allergists and apply skin biopsy techniques to rule out differential diagnosis.
6.  Examine current treatment for Eosinophilic Esophagitis and update attendees on improved treatment options.
7.  Demonstrate what COPD is and assess whether is associated with marijuana smoking and review literature for associations between lung cancer and marijuana smoking.
8.  Demonstrate the safety and efficacy of AIT in polysensitized patients.
9.  Illustrate itch of different types and examine atopic itch and its new management.
10.  Examine current treatment for Hereditary Angioedema and update attendees on improved treatment options.
11.  Analyze specific PIDs and their connection to autoimmune disease in order to improve the clinical recognition and prompt treatment.
12. Review the clinical phenotype of nasal polyposis and examine the emerging concepts in dysregulation in the Th2 pathway contributing to the pathophysiology.
13.  Review symptoms and treatment options for allergic rhinitis and differentiating between entopy and spontaneous reactions.
14.  To summarize the current management and therapies for IgE-mediated food allergy and review key findings from clinical trials and other research studies in food allergy treatment.
15.  Examine current treatment for eczema, urticaria and angioedema, and update attendees on improved treatment options.
16.  Summarize the history and research of alpha gal and demonstrate improvement in the management of care of a patient with alpha gal.

Additional information
Disclosure: 

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. 

All identified conflicts of interest have been resolved.

Lee S. Clore, Jr., MD – CME Planner, Moderator
Speaker – Boehringer Ingelheim, Genentech, GSK, Regeneron
Advisor Board Member – GSK

Patricia Stewart, MD – Moderator
Speaker – Genentech
Advisor Board Member – AstraZeneca


Michael Blaiss, MD – Speaker
Consultant – ALK, Merck and Stallergenes/Greer

Scott Commins, MD – Speaker
Speaker - Genentech

Douglas T. Johnston, DO – Speaker
Consultant/Advisor – Aimmune, Allakos, BioCryst, CSL Behring, Pharming, Shire/Takeda, Regenexbio, Kalvista
Speaker – CSL Behring, Pharming, Shire/Takeda, Pfizer

Rohit Katial, MD – Speaker
Employee - AstraZeneca

Dennis Ledford, MD – Speaker
Consultant – AstraZeneca, Genentech
Speaker – ALK, AstraZeneca, Boehringer Ingelheim, Genentech, Novartis, Sanofi/Regeneron
Advisory Board –AstraZeneca
Independent Contractor – Galderma

Niraj Patel, MD – Speaker
Speaker – Shire, CSL Behring
Other:  Research Studies – Shire

Marc Serota, MD – Speaker
Consultant – Sanofi Genzyme, Pfizer, Regeneron, Genentech

Brian Vickery, MD – Speaker
Consultant – Aimmune, AllerGenis, Reacta Biosciences
Advisory Board Member – Aimmune 

Gil Yosipovitch, MD – Speaker
Consultant/Advisory Board Member:  Sanofi, Regeneron, Menlo, Trevi, Sienna, Kiniksa, Eli Lilly, Novartis, Pfizer, Sun Pharma, Leo, AbbVie

The following have nothing to disclose:
Jean L. Owen, MBA – Meeting Planner
Holly McPherson, MD – CME Planner, Moderator

Course summary
Available credit: 
  • 12.75 AMA PRA Category 1 Credit™
  • 12.75 Attendance
Course opens: 
09/19/2019
Course expires: 
09/22/2021
Event starts: 
09/19/2019 - 5:00pm
Event ends: 
09/22/2019 - 12:00pm
Cost:
$0.00
Rating: 
0
Omni Amelia Island
39 Beach Lagoon Road
Amelia Island, FL 32034
United States
+1 (904) 261-6161

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Southeastern Allergy, Asthma and Immunology (SEAAIS).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of  12.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 12.75 AMA PRA Category 1 Credit™
  • 12.75 Attendance

Accreditation Period

Course opens: 
09/19/2019
Course expires: 
09/22/2021

Price

Cost:
$0.00
Please login or create an account to take this course.